GlassScriptPhysician profile
Morgan Jones
NPI 1265954499
$754.82
in general payments reported to CMS, 2019-2025
18 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $61.42 · 2023: $30.88 · 2024: $72.80 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $137.66 | 2024-2025 | General - Tachy, Rotapro, Avvigo Guidance System |
| Abbvie INC. | $89.02 | 2021-2025 | |
| Novo Nordisk INC | $87.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $67.75 | 2021-2023 | Farxiga |
| Pfizer INC. | $56.71 | 2021-2023 | |
| Lilly USA, LLC | $50.12 | 2021-2022 | |
| Neurelis, INC. | $45.61 | 2024 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $27.60 | 2021 | |
| Smith+Nephew, INC. | $24.90 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.76 | 2021 | |
| Currax Pharmaceuticals LLC | $23.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.87 | 2021 | |
| Eisai INC. | $18.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.78 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.29 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.06 | 2021 | |
| Glaxosmithkline, LLC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.